Advertisement
Australia markets closed

  • ALL ORDS

    7,837.40
    -100.10 (-1.26%)
     

  • ASX 200

    7,575.90
    -107.10 (-1.39%)
     

  • AUD/USD

    0.6547
    +0.0023 (+0.36%)
     

  • OIL

    83.96
    +0.39 (+0.47%)
     

  • GOLD

    2,353.40
    +10.90 (+0.47%)
     

  • Bitcoin AUD

    98,401.08
    +245.29 (+0.25%)
     

  • CMC Crypto 200

    1,387.69
    -8.85 (-0.63%)
     

  • AUD/EUR

    0.6097
    +0.0024 (+0.39%)
     

  • AUD/NZD

    1.0976
    +0.0018 (+0.17%)
     

  • NZX 50

    11,805.09
    -141.34 (-1.18%)
     

  • NASDAQ

    17,430.50
    -96.30 (-0.55%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • Dow Jones

    38,085.80
    -375.12 (-0.98%)
     

  • DAX

    17,917.28
    -171.42 (-0.95%)
     

  • Hang Seng

    17,707.57
    +423.03 (+2.45%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

Intra-Cellular Therapies to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

Intra-Cellular Therapies Inc.
·1-min read

NEW YORK, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to participate in a fireside chat at the Morgan Stanley 18th Annual Global Healthcare Conference on Wednesday, September 16, 2020 at 2:00 pm ET.

The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.

About Intra-Cellular Therapies

Intra-Cellular Therapies is a biopharmaceutical company founded on Nobel prize-winning research that allows us to understand how therapies affect the inner-workings of cells in the body. The company leverages this intracellular approach to develop innovative treatments for people living with complex psychiatric and neurologic diseases.

ADVERTISEMENT

Contact

Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
646-440-9333

Burns McClellan, Inc.
Lisa Burns
jgrimaldi@burnsmc.com
212-213-0006

Media Inquiries:

Ana Fullmer
Corporate Media Relations W20wcg
afullmer@wcgworld.com
202-507-0130